Farmers Trust Co. Sells 264 Shares of Solventum Co. (NYSE:SOLV)

Farmers Trust Co. cut its holdings in Solventum Co. (NYSE:SOLV) by 0.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 81,334 shares of the company’s stock after selling 264 shares during the period. Farmers Trust Co.’s holdings in Solventum were worth $5,373,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Copeland Capital Management LLC purchased a new stake in shares of Solventum in the third quarter worth about $26,000. Modus Advisors LLC bought a new position in Solventum in the 4th quarter valued at $25,000. Mather Group LLC. purchased a new position in shares of Solventum during the 3rd quarter valued at $27,000. Hollencrest Capital Management bought a new position in shares of Solventum in the second quarter worth $25,000. Finally, True Wealth Design LLC boosted its stake in Solventum by 23,550.0% during the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock valued at $33,000 after buying an additional 471 shares during the period.

Solventum Stock Performance

Shares of NYSE:SOLV traded down $0.45 during trading on Wednesday, reaching $68.96. 2,486,881 shares of the company traded hands, compared to its average volume of 1,123,025. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05. The business’s fifty day moving average is $69.59 and its 200-day moving average is $64.63.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on SOLV shares. Morgan Stanley raised their target price on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Wolfe Research assumed coverage on shares of Solventum in a research report on Thursday, September 26th. They issued a “peer perform” rating for the company. Piper Sandler raised their price target on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research report on Friday, November 8th. Mizuho initiated coverage on Solventum in a report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price objective for the company. Finally, Stifel Nicolaus initiated coverage on Solventum in a report on Tuesday, October 8th. They set a “buy” rating and a $82.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $68.29.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.